Using a diverse human gut community, researchers investigated how gut microbiota interspecies interactions affected the response of Clostridioides difficile to vancomycin and metronidazole. Findings ...

The pathogen C. diff - the most common cause of health care-associated infectious diarrhea - can use a compound that kills the human gut's resident microbes to survive and grow, giving it a ...

Rachel works as a CRNA where she provides anesthesia care across the lifespan, including pediatric anesthesia, with a primary focus on orthopedic anesthesia. She is also an Assistant Professor at the ...

Most antibiotics are double-edged swords. Besides killing the pathogen they are prescribed for, they also decimate beneficial bacteria and change the composition of the gut microbiome. As a result, ...

"But when colonizing the gut, C. diff also produces two large toxins, TcdA and TcdB, which cause inflammation. We wanted to know if these inflammation-causing toxins actually give C. diff a survival ...

Iron storage “spheres” inside the bacterium C. diff — the leading cause of hospital-acquired infections — could offer new targets for antibacterial drugs to combat the pathogen. A team of Vanderbilt ...

Matthew Munneke, left, and Eric Skaar, PhD, MPH, use anaerobic chambers to study bacteria like C. diff that die in the presence of oxygen. The pathogen C. diff — the most common cause of health ...

The bacterium Clostridioides difficile, which was formerly named Clostridium difficile and is now commonly known as C. difficile or simply C. diff, is a common microorganism found in the environment.

New study reveals at a molecular level how fidaxomicin selectively targets C. Diff bacteria while sparing the innocent bacterial bystanders of the gut microbiome. Most antibiotics are double-edged ...

The study of Clostridium difficile infection (CDI) continues to reveal intricate details of its pathogenesis, epidemiology and potential novel therapies. Research has elucidated how the bacterium, ...

Finch Therapeutics' phase 3 trial for a Clostridioides difficile med has been placed on clinical hold by the FDA as the agency requests more information on how the biotech screens the donor-derived ...

The medicine offers a new, potentially life-saving option for a difficult-to-treat condition. “This is such a groundbreaking advancement in the field of medicine,” Sahil Khanna, MBBS, a ...